Patents by Inventor Mark Palermo

Mark Palermo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimeric IAP inhibitors
    Patent number: 8445440
    Abstract: The present invention provides compounds of formula M-L-M? (where M and M? are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventors: Christopher Straub, Zhuoliang Chen, Mark Palermo
  • Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7825115
    Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: November 2, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
  • Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
    Publication number: 20080108654
    Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Application
    Filed: January 10, 2008
    Publication date: May 8, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marcel PATEK, Anil NAIR, Augustin HITTINGER, Conception NEMECEK, Daniel BOND, Greg HARLOW, Herve BOUCHARD, Jacques MAUGER, Jean-Luc MALLERON, Mark PALERMO, Fahad AL-OBEIDI, Thomas FAITG, Hartmut STROBEL, Sven RUF, Kurt RITTER, Youssef EL-AHMAD, Dominique LESUISSE
  • Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7354933
    Abstract: The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: April 8, 2008
    Assignee: Aventis Pharma SA
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
  • Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
    Publication number: 20060128632
    Abstract: The present disclosure relates to XIAP inhibitor compounds of the formula I wherein the substituents are as described in the specification. The inventive compounds are useful as therapeutic agents for the treatment of proliferative disorders, including cancer.
    Type: Application
    Filed: July 1, 2003
    Publication date: June 15, 2006
    Inventors: Sushil Sharma, Leigh Zawel, Mark Palermo, Nagarajan Chandeamouli, Kenneth Bair
  • Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (IAP)
    Publication number: 20060052311
    Abstract: The present disclosure relates to XIAP inhibitor compounds of the formula I wherein the substituents are as described in the specification. The inventive compounds are useful as therapeutic agents for the treatment of proliferative disorders, including cancer.
    Type: Application
    Filed: August 12, 2005
    Publication date: March 9, 2006
    Inventors: Sushil Sharma, Leigh Zawel, Mark Palermo, Nagarajan Chandramouli, Kenneth Bair
  • Organic compounds
    Publication number: 20050234042
    Abstract: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I
    Type: Application
    Filed: April 6, 2005
    Publication date: October 20, 2005
    Inventors: Mark Palermo, Sushil Sharma, Christopher Straub, Run-Ming Wang, Leigh Zawel, Yanlin Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark Charest, Feng He
  • Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Publication number: 20040248884
    Abstract: The present invention relates to a cyclic urea compound of formula I: 1
    Type: Application
    Filed: February 2, 2004
    Publication date: December 9, 2004
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse